In another study luminal A tumors were 82.8%, luminal B (HR−/HER2+) tumors found in 6.2%, and basal-like (HR−/HER2−) tumors were found in 9.6% of the male breast cancer cohort [19]. Here, ERBB2 is linked to breast cancer.